5:19 PM
Jun 23, 2016
 |  BC Extra  |  Company News

CDC panel snubs AZ's FluMist

CDC's Advisory Committee on Immunization Practices (ACIP) recommended against use of FluMist from AstraZeneca plc (LSE:AZN; NYSE:AZN) to prevent seasonal influenza during the 2016-17 flu season. The intranasal live attenuated influenza vaccine (LAIV) is the only non-injection-based flu vaccine available in the U.S.

CDC said ACIP based its vote on weak efficacy data in children aged 2-17 in the last three flu seasons. The agency said FluMist showed no measurable protective benefit in the 2015-16 season,...

Read the full 380 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >